Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India.
Drug Dev Ind Pharm. 2011 Nov;37(11):1329-38. doi: 10.3109/03639045.2011.572889. Epub 2011 Jun 27.
Intestinal targeted mucoadhesive microsphere of probiotics may provide numerous associated health benefits.
To develop mucoadhesive microspheres that will deliver viable probiotic cells into gut protectively against harsh environmental conditions of stomach for extended period.
Core mucoadhesive microspheres of Bacillus coagulans were prepared using hypromellose, following coacervation and phase separation technique and were then coated with hypromellose phthalate to achieve their site-specific release. Microspheres were evaluated for percent yield, entrapment efficiency, surface morphology, particle size and size distribution, flow property, swelling property, mucoadhesion property by the in vitro wash-off and the ex vivo mucoadhesive strength tests, in vitro release profile and release kinetic, in vivo probiotic activity, and stability. The values for kinetic constant and regression coefficient of model-dependent approaches and the difference factor, the similarity factor, and the Rescigno index of model-independent approaches were determined for accessing and comparing in vitro performance.
Microsphere formulation batches have percent yield value between 56.26% and 69.13% and entrapment efficiency value between 66.95% and 77.89%. Microspheres were coarser with spherical shape having mean particle size from 28.03 to 48.31 μm. In vitro B. coagulans release profile follows zero-order kinetics and depends on the grade of hypromellose and the B. coagulans-to-hypromellose ratio. Experimental microspheres rendered adequate stability to B. coagulans at room temperature.
Microspheres had delivered B. coagulans in simulated intestinal condition following zero-order kinetics, protectively in simulated gastric condition, exhibiting appreciable mucoadhesion in intestinal condition, which could be useful to achieve site-specific delivery for extended period.
肠道靶向益生菌黏膜粘附微球可能提供许多相关的健康益处。
开发黏膜粘附微球,将活菌益生菌细胞递送至肠道,以在较长时间内保护其免受胃部恶劣环境的影响。
采用羟丙甲纤维素,通过凝聚和相分离技术制备凝结芽孢杆菌的核心黏膜粘附微球,然后用羟丙甲纤维素邻苯二甲酸酯对其进行包衣,以实现其定位释放。通过体外冲洗和离体黏膜粘附强度试验评估微球的产率、包封效率、表面形态、粒径和粒径分布、流动性、溶胀性、黏膜粘附性,通过体外释放曲线和释放动力学、体内益生菌活性和稳定性进行评估。通过动力学常数和模型依赖方法的回归系数、差异因子、相似因子和无模型独立方法的雷斯西诺指数来确定和比较体外性能。
微球制剂批的产率值在 56.26%至 69.13%之间,包封效率值在 66.95%至 77.89%之间。微球较粗糙,呈球形,平均粒径为 28.03 至 48.31μm。体外凝结芽孢杆菌释放曲线遵循零级动力学,取决于羟丙甲纤维素的等级和凝结芽孢杆菌与羟丙甲纤维素的比例。实验微球在室温下对凝结芽孢杆菌具有足够的稳定性。
微球在模拟肠道条件下以零级动力学释放凝结芽孢杆菌,在模拟胃条件下保护性释放,在模拟肠道条件下表现出明显的黏膜粘附性,这可能有助于实现延长时间的定位释放。